StockMarketWire.com - Angle said its cell separation technology was being used in a study conducted by the Hellenic Oncology Research Group.

The study involved 50 operable early stage non small cell lung cancer patients having liquid biopsy blood tests prior to surgery, one month after surgery and then every three to six months until relapse.

The study was scheduled to complete in December 2021, the company said.

Cancer cells harvested from patient blood using the Parsortix system would be analysed using qRT-PCR and FISH to identify tumor clonal evolution with the intention of identifying both predictors of relapse and indications of suitable treatment, Angle added.


At 8:38am: [LON:AGL] Angle PLC share price was +0.5p at 67.5p



Story provided by StockMarketWire.com